Horizon Pharma plc is looking to add approved drugs Ravicti (glycerol phenylbutyrate) and Buphenyl (sodium phenylbutyrate) to its orphan drug business by acquiring the outstanding shares of developer Hyperion Therapeutics Inc. for $46 apiece in cash, or approximately $1.1 billion.